Publications for Leslie Citrome nntman@gmail.com
Citrome, L. (2013). Handbook of treatment-resistant schizophrenia. London, England: Springer Healthcare.
Citrome, L. (2013). Holiday time! Evidence-based flying revisited. International Journal of Clinical Practice, 67(12), 1213-1214. doi:10.1111/ijcp.12348
Citrome, L. (2013). Inhaled loxapine for agitation. Current Psychiatry, 12(2), 31-36. This material can be found here.
Citrome, L. (2013). Levomilnacipran for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 67(11), 1089-1104. doi:10.1111/ijcp.12298
Citrome, L. (2013). Meta-analyses: Editor's dream or nightmare? International Journal of Clinical Practice, 67(11), 1069-1070. doi:10.1111/ijcp.12324
Citrome, L. (2013). New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics, 13(7), 767-783. doi:10.1586/14737175.2013.811984
Citrome, L. (2013). Preserving books by destroying them: a foray into digitization of a professional library. International Journal of Clinical Practice, 67(10), 927-929.
Citrome, L., & Ketter, T. A. (2013). When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. International Journal of Clinical Practice, 67(5), 407-411. doi:10.1111/ijcp.12142
Citrome, L., Collins, J. M., Nordstrom, L., Rosen, E. J., Baker, R., Nadkarni, A., & Kalsekar, I. (2013). Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. Journal of Clinical Psychiatry, 74(12), 1199-1206. doi:10.4088/JCP.13m08642
Citrome, L., Goldberg, J. F., & Portland, K. B. (2013). Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 151(2), 409-417. doi:10.1016/j.jad.2013.06.027
Citrome, L., Kalsekar, I., Guo, Z., Laubmeier, K., & Hebden, T. (2013). Diagnoses associated with use of atypical antipsychotics in a commercial health plan: A claims database analysis. Clinical Therapeutics, 35(12), 1867-1875. doi:10.1016/j.clinthera.2013.09.006
Citrome, L., Peselow, E. D., & Glick, I. D. (2013). Asenapine. In A. F. Schatzenberg & C. B. Nemeroff (Eds.), Essentials of clinical psychopharmacology (3rd ed., pp. 367-375). Arlington, VA: American Psychiatric Publishing.
Citrome, L., Weiden, P. J., McEvoy, J. P., Correll, C. U., Cucchiaro, J., Hsu, J., & Loebel, A. (2013). Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: A 6-month, open-label, extension study. CNS Spectrums, 1-10. doi:10.1017/S109285291300093X
Goff, D. C., McEvoy, J. P., Citrome, L., Mech, A. W., Bustillo, J. R., Gil, R., . . . Macklin, E. A. (2013). High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: The ZEBRAS study. Journal of Clinical Psychopharmacology, 33(4), 485-490. doi:10.1097/JCP.0b013e3182977308
Lindenmayer, J. P., Nasrallah, H., Pucci, M., James, S., & Citrome, L. (2013). A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities. Schizophrenia Research, 147(2-3), 241-252. doi:10.1016/j.schres.2013.03.019
McEvoy, J. P., Citrome, L., Hernandez, D., Cucchiaro, J., Hsu, J., Pikalov, A., & Loebel, A. (2013). Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study. Journal of Clinical Psychiatry, 74(2), 170-179. doi:10.4088/JCP.12m07992
Stahl, S. M., Morrissette, D. A., Citrome, L., Saklad, S. R., Cummings, M. A., . . . Warburton, K. (2013). "Meta-guidelines" for the management of patients with schizophrenia. CNS Spectrums, 18(3), 150-162. doi:10.1017/S109285291300014X
